A Closer Look At The US Pricing Pushback
This article was originally published in Scrip
Critics of high prescription drug prices are making headlines in the US, and politicians on the presidential campaign trail and on Capitol Hill are talking about government-imposed price controls. But the real news may be unfolding behind the scenes in the private health insurance market, as Cathy Kelly finds out.
You may also be interested in...
Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.